Nivalis Therapeutics (NVLS) Takes a Significant Tumble; Thor Industries (THO) Achieves Strong Profit Growth


Nivalis Therapeutics Inc. (Nasdaq:NVLS) shares slumped more than 35% to reach one-year low levels in after-hours trading Monday as the company said that a Phase 2 trial evaluating its investigational small molecule cavosonstat in adult patients with cystic fibrosis has failed to meet the primary endpoint.

NVLS stock finished the regular session in negative territory by 0.48% (or -$0.03) at $6.25 with a total volume of 493,578 shares traded, representing a large increase in activity versus its average volume (3m) of 74,340 shares.

Nivalis Therapeutics, which focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis, has 15.54M Shares Outstanding. At close on Monday, the clinical-stage pharmaceutical company had a Market Capitalization of $97.61M and NVLS stock 52-week range was between $3.68 and $9.45 per share



Shares of Thor Industries, Inc. (NYSE:THO) soared over 9% to touch a new 52-week high in the extended session Monday after the company delivered in its financial results quarterly profit and revenue numbers well-above Wall Street analysts’ expectations.

For its first quarter fiscal 2017, Thor Industries posted revenues of $1.71 billion, a 65.82% increase year over year, and net income of $78.7 million, or $1.49 per diluted share, compared to net income of $50.5 million, or $0.96 per diluted share, easily surpassing the Capital IQ Consensus Estimate of $1.23 earnings per share on revenues of $1.50 billion for the period.

THO stock closed at $90.44, down $0.23 (or -0.25%), and 1.34M of its shares changed hands during the day.

Thor Industries, which designs, manufactures, and sells recreational vehicles, and related parts and accessories primarily in the United States and Canada, has 52.59M Shares Outstanding, Market Capitalization (intraday) of $4.76B and THO stock one-year range is from $47.56 to $91.99 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at